Cargando…
Validation of the “Six-and-Twelve” Prognostic Score in Transarterial Chemoembolization–Treated Hepatocellular Carcinoma Patients
The “six-and-twelve” prognostic score was proposed recently to predict survival rate in patients with unresectable hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE). However, it has not been validated externally. We validated this score and previous prognostic scores...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899857/ https://www.ncbi.nlm.nih.gov/pubmed/33605612 http://dx.doi.org/10.14309/ctg.0000000000000310 |
_version_ | 1783654096380624896 |
---|---|
author | Kaewdech, Apichat Sripongpun, Pimsiri Cheewasereechon, Natcha Jandee, Sawangpong Chamroonkul, Naichaya Piratvisuth, Teerha |
author_facet | Kaewdech, Apichat Sripongpun, Pimsiri Cheewasereechon, Natcha Jandee, Sawangpong Chamroonkul, Naichaya Piratvisuth, Teerha |
author_sort | Kaewdech, Apichat |
collection | PubMed |
description | The “six-and-twelve” prognostic score was proposed recently to predict survival rate in patients with unresectable hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE). However, it has not been validated externally. We validated this score and previous prognostic scores in Thai HCC patients treated with TACE. METHODS: We identified all HCC patients who underwent TACE between January 2007 and December 2018 at our hospital. The inclusion criteria were treatment-naive, unresectable HCC BCLC-A and BCLC-B; if cirrhosis was present, Child-Pugh score ≤7; and baseline performance status 0–1. RESULTS: Of 716 HCC patients undergoing TACE, 281 (mean age, 61.1 years; 73.0% men, 92.2% with cirrhosis) were eligible. Approximately half of the patients had hepatitis B virus. Median overall survival was 20.3 (95% confidence interval, 16.4–26.3) months. By stratifying with the “six-and-twelve” score (≤6, >6–12, >12), median (95% confidence interval) overall survival was 35.1 (26.4–53.0), 16.0 (11.6–22.6), and 7.6 (5.4–14.9) months, respectively. Area under the receiver operating characteristic curves (AUROCs) predicting death at 1, 2, and 3 years for the “six-and-twelve” score were 0.714, 0.700, and 0.688, respectively. Compared with the other currently available scores, the AUROC predicting death at 1 year for the “six-and-twelve” score was the most predictive and better than other models except the up-to-seven model. DISCUSSION: Our study confirms the value of the “six-and-twelve” score to predict survival rate of unresectable HCC treated with TACE. However, in our validation cohort, AUROC of the “six-and-twelve” score was slightly lower than that of the original Chinese cohort (0.73). |
format | Online Article Text |
id | pubmed-7899857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-78998572021-02-23 Validation of the “Six-and-Twelve” Prognostic Score in Transarterial Chemoembolization–Treated Hepatocellular Carcinoma Patients Kaewdech, Apichat Sripongpun, Pimsiri Cheewasereechon, Natcha Jandee, Sawangpong Chamroonkul, Naichaya Piratvisuth, Teerha Clin Transl Gastroenterol Article The “six-and-twelve” prognostic score was proposed recently to predict survival rate in patients with unresectable hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE). However, it has not been validated externally. We validated this score and previous prognostic scores in Thai HCC patients treated with TACE. METHODS: We identified all HCC patients who underwent TACE between January 2007 and December 2018 at our hospital. The inclusion criteria were treatment-naive, unresectable HCC BCLC-A and BCLC-B; if cirrhosis was present, Child-Pugh score ≤7; and baseline performance status 0–1. RESULTS: Of 716 HCC patients undergoing TACE, 281 (mean age, 61.1 years; 73.0% men, 92.2% with cirrhosis) were eligible. Approximately half of the patients had hepatitis B virus. Median overall survival was 20.3 (95% confidence interval, 16.4–26.3) months. By stratifying with the “six-and-twelve” score (≤6, >6–12, >12), median (95% confidence interval) overall survival was 35.1 (26.4–53.0), 16.0 (11.6–22.6), and 7.6 (5.4–14.9) months, respectively. Area under the receiver operating characteristic curves (AUROCs) predicting death at 1, 2, and 3 years for the “six-and-twelve” score were 0.714, 0.700, and 0.688, respectively. Compared with the other currently available scores, the AUROC predicting death at 1 year for the “six-and-twelve” score was the most predictive and better than other models except the up-to-seven model. DISCUSSION: Our study confirms the value of the “six-and-twelve” score to predict survival rate of unresectable HCC treated with TACE. However, in our validation cohort, AUROC of the “six-and-twelve” score was slightly lower than that of the original Chinese cohort (0.73). Wolters Kluwer 2021-02-18 /pmc/articles/PMC7899857/ /pubmed/33605612 http://dx.doi.org/10.14309/ctg.0000000000000310 Text en © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Kaewdech, Apichat Sripongpun, Pimsiri Cheewasereechon, Natcha Jandee, Sawangpong Chamroonkul, Naichaya Piratvisuth, Teerha Validation of the “Six-and-Twelve” Prognostic Score in Transarterial Chemoembolization–Treated Hepatocellular Carcinoma Patients |
title | Validation of the “Six-and-Twelve” Prognostic Score in Transarterial Chemoembolization–Treated Hepatocellular Carcinoma Patients |
title_full | Validation of the “Six-and-Twelve” Prognostic Score in Transarterial Chemoembolization–Treated Hepatocellular Carcinoma Patients |
title_fullStr | Validation of the “Six-and-Twelve” Prognostic Score in Transarterial Chemoembolization–Treated Hepatocellular Carcinoma Patients |
title_full_unstemmed | Validation of the “Six-and-Twelve” Prognostic Score in Transarterial Chemoembolization–Treated Hepatocellular Carcinoma Patients |
title_short | Validation of the “Six-and-Twelve” Prognostic Score in Transarterial Chemoembolization–Treated Hepatocellular Carcinoma Patients |
title_sort | validation of the “six-and-twelve” prognostic score in transarterial chemoembolization–treated hepatocellular carcinoma patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899857/ https://www.ncbi.nlm.nih.gov/pubmed/33605612 http://dx.doi.org/10.14309/ctg.0000000000000310 |
work_keys_str_mv | AT kaewdechapichat validationofthesixandtwelveprognosticscoreintransarterialchemoembolizationtreatedhepatocellularcarcinomapatients AT sripongpunpimsiri validationofthesixandtwelveprognosticscoreintransarterialchemoembolizationtreatedhepatocellularcarcinomapatients AT cheewasereechonnatcha validationofthesixandtwelveprognosticscoreintransarterialchemoembolizationtreatedhepatocellularcarcinomapatients AT jandeesawangpong validationofthesixandtwelveprognosticscoreintransarterialchemoembolizationtreatedhepatocellularcarcinomapatients AT chamroonkulnaichaya validationofthesixandtwelveprognosticscoreintransarterialchemoembolizationtreatedhepatocellularcarcinomapatients AT piratvisuthteerha validationofthesixandtwelveprognosticscoreintransarterialchemoembolizationtreatedhepatocellularcarcinomapatients |